Short Wave Pharma Overview
Short Wave Pharma is a biopharmaceutical company developing novel formulations of psilocybin and additional APIs, along with customized delivery methods, for patients living with mental health disorders, neurodegenerative diseases, chronic pain, and any other medical conditions for which psilocybin is known to have a positive effect. Short Wave Pharma has begun preclinical studies related to its product for anorexia nervosa. The company’s future programs include the development of novel formulations and delivery approaches for chronic pain and neurodegenerative diseases.
Latest News
growth-positive
Biopharma company Short Wave partnering in clinical trial for eating disorders with Sheba Fund | CTech
Short Wave Pharma has signed a clinical trial agreement with the Sheba Fund for Health Services and Research to study the safety and feasibility of psilocybin-assisted psychotherapy for the treatment of anorexia nervosa. The trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment. Short Wave Pharma develops patent-pending psychedelic compositions and methods of delivery and will be the exclusive commercial partner for the trial. Anorexia nervosa is a life-threatening disease and a severe eating disorder that affects about 0.5-1% of the population.
PartnersCustomers
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | Undisclosed |
| Last funding | Undisclosed |
| Stage | Pre-Funding |
| Rounds | 0 |
| Investors | 0 |
Team Members
2
Employees: 1-10
Web & Social Links
| Website | shortwavelifesciences.com |
Locations
Sderot Bialik 39, Ramat HaSharon, Israel
1 Adelaide St E, Toronto, ON M5C 2V9, Canada
1 Adelaide St E, Toronto, ON M5C 1J4, Canada
Photos & Videos
1 item(s)
